Many studies have shown that low flux nitric oxide (NO) produced by inducible NO synthase (iNOS/NOS2) in various tumors, including glioblastomas, can promote angiogenesis, cell proliferation, and migration/invasion. Minimally invasive, site-specific photodynamic therapy (PDT) is a highly promising anti-glioblastoma modality. Recent research in the authors’ laboratory has revealed that iNOS-derived NO in glioblastoma cells elicits resistance to 5-aminolevulinic acid (ALA)-based PDT, and moreover endows PDT-surviving cells with greater proliferation and migration/invasion aggressiveness. In this contribution, we discuss iNOS/NO antagonism to glioblastoma PDT and how this can be overcome by judicious use of pharmacologic inhibitors of iNOS activity or transcription.
CITATION STYLE
Fahey, J. M., & Girotti, A. W. (2019, February 1). Nitric oxide antagonism to anti-glioblastoma photodynamic therapy: Mitigation by inhibitors of nitric oxide generation. Cancers. MDPI AG. https://doi.org/10.3390/cancers11020231
Mendeley helps you to discover research relevant for your work.